If you have been reading about thymosin alpha-1 and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-02-22. Numbers and descriptions here follow the published literature rather than marketing material.
Whether the free 28-residue peptide circulates in human tissue remains debated. The best-documented human source is prothymosin alpha, a larger acidic protein that carries the sequence at its N-terminus. Reports of measurable peptide levels in serum and lymphoid tissue exist, yet some of that signal may come from cross-reacting fragments or from the parent protein. Most reviews therefore treat prothymosin alpha as the established human molecule and describe independent circulation of the small peptide as an unresolved question.
Immunological studies connect the peptide to multiple parts of the immune response. It has been reported to engage Toll-like receptor signaling, to promote dendritic cell maturation, and to influence the balance of T helper cell subsets. Changes in natural killer cell activity and in cytokine release appear in cell culture and animal models. These observations describe broad immunomodulatory behavior rather than a single defined receptor target, and the primary molecular interaction has not been settled.
Thymosin alpha-1 is a synthetic 28-amino-acid peptide whose sequence was first identified in extracts of bovine thymus tissue during the 1970s. The chain carries an acetyl group on its N-terminal serine. Its acidic residue content is high, which produces strong water solubility and an isoelectric point well below neutrality. Material supplied for laboratory and clinical use is manufactured by solid-phase peptide synthesis rather than purified from animal tissue. Different salt forms, such as the acetate, alter the counter-ion content without changing the peptide backbone.
The peptide was described in the 1970s as a component of thymic extracts, and early research focused on restoring immune function in immunodeficiency states. A synthetic version entered clinical development in the 1980s and is approved as a drug in several countries for conditions such as chronic hepatitis B and certain immunodeficiencies. Approval status varies widely by jurisdiction, and in the United States it is not an approved therapeutic. Regulatory and clinical positions differ, so statements about efficacy should be tied to specific indications and studies.
Thymosin alpha-1 is a synthetic peptide of 28 amino acids, corresponding to the N-terminal fragment of prothymosin alpha. Its sequence begins with acetylation at the N-terminus, a modification that affects stability and receptor interaction. The peptide is acidic, with a calculated isoelectric point near 4.2, and carries no disulfide bonds, so its secondary structure is largely flexible in solution. Molecular mass is approximately 3108 daltons. The native form was first isolated from bovine thymus tissue, while pharmaceutical material is produced by solid-phase peptide synthesis.
Within the immune system, the peptide acts on several cell types rather than a single target. Reported activities include promotion of T-cell maturation, enhancement of natural killer cell activity, and modulation of cytokine production by dendritic cells and macrophages. Some of these effects appear to operate through toll-like receptor signaling, though the precise receptor-level mechanism remains debated. Whether the observed immune changes translate into clinical benefit is a separate question and depends on the indication studied.
| Property | Value | Notes |
|---|---|---|
| Amino acid length | 28 residues | Single chain with an acetylated N-terminus |
| Molecular mass | Approximately 3,108 Da | Small shifts occur with counter-ion and water content |
| Isoelectric point | Around 3.5 | Low value follows from the many acidic residues |
| Parent molecule | N-terminal region of prothymosin alpha | Free circulating form in humans is not firmly established |
| Common synonyms | Thymalfasin; T alpha 1 | Older literature also uses the full spelled-out form |
The peptide was identified during work in the 1970s on thymosin fraction 5, a partially purified extract of calf thymus. Investigators separated that mixture and characterized individual components, one of which they named thymosin alpha-1. The same compound later received the international nonproprietary name thymalfasin. Commercial material is produced by solid-phase peptide synthesis rather than by extraction, so synthetic and natural forms share an identical sequence. Naming conventions vary across the literature, and readers should distinguish the alpha-1 peptide from other thymosins that have unrelated sequences and functions.
Thymosin beta-4 is a separate 43-residue peptide that binds actin and participates in cell migration; it shares no sequence similarity with thymosin alpha-1 despite the common family name. Other preparative materials, such as thymosin fraction 5 and thymopoietin, contain distinct mixtures or peptides. The shared thymosin label reflects the tissue of origin used in early purification, not a common structural core. Treating these molecules as interchangeable is a frequent source of confusion in laboratory reports and in popular summaries alike.
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography, which separates the target peptide from truncated or chemically modified byproducts. Mass spectrometry confirms the expected molecular mass and can indicate acetylation state or sequence errors. Amino acid analysis and peptide mapping supply complementary sequence-level information, while endotoxin testing is relevant for preparations intended for cell or animal work. Purity figures reported by suppliers refer to the method used and are not directly comparable across laboratories unless conditions are stated.
Lyophilized material is typically treated as a hygroscopic solid that should be brought to room temperature before the container is opened, which limits condensation on the powder. Reconstitution is commonly done with sterile water or a buffered diluent, and gentle mixing is preferred over vigorous agitation to reduce foaming and surface adsorption. Because peptides can bind to plastic and glass, diluents containing a small amount of carrier protein are sometimes used in laboratory work. Working solutions are generally aliquoted and prepared fresh rather than subjected to repeated freezing and thawing.
Laboratory work indicates that the peptide acts on cells of both the innate and adaptive immune systems. Reported effects include signalling through Toll-like receptors on dendritic cells, enhanced T-cell maturation, and increased natural killer cell activity. These actions are described largely from cell-culture and animal experiments, and the precise receptor-level events remain incompletely defined. Studies in humans have generally measured immune markers rather than a single defined molecular target. The resulting picture remains partly descriptive.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Results across trials have been mixed, and several studies were small or conducted under differing protocols. Regulatory status varies by country, and the compound is not approved in every jurisdiction where it is studied. Evidence for any single indication should be read with attention to sample size and endpoint choice.
The resulting proposed law did not get through the Congress of the United States for five years, but was rapidly enacted into law following the public outcry over the 1937 Elixir Sulfanilamide tragedy, in which over 100 people died after using a drug formulated with a toxic, untested solvent. President Franklin Delano Roosevelt signed the Federal Food, Drug, and Cosmetic Act into law on June 24, 1938. The new law significantly increased federal regulatory authority over drugs by mandating a pre-market review of the safety of all new drugs, as well as banning false therapeutic claims in drug labeling without requiring that the FDA prove fraudulent intent. The law also authorized the FDA to issue minimum food standards of identity for all mass-produced foods to reduce food fraud. By the 1970s, the FDA began pivoting from setting detailed standards of identity for foods to requiring informative labels – an ‘informational turn’ in food regulation aimed at steering food markets through disclosure rather than direct control. Later, in the 1990s, the FDA would update these information label rules with the introduction of the Nutrition Facts panel. Soon after passage of the 1938 Act, the FDA began to designate certain drugs as safe for use only under the supervision of a medical professional, and the category of "prescription-only" drugs was securely codified into law by the Durham-Humphrey Amendment in 1951. These developments confirmed extensive powers for the FDA to enforce post-marketing recalls of ineffective drugs.
The Golden Gate assembly protocol was defined by Engler et al. 2008 to define a DNA assembly method that would give a final construct without a scar sequence, while also lacking the original restriction sites. This allows the protein to be expressed without containing unwanted protein sequences which could negatively affect protein folding or expression. By using the BsaI restriction enzyme that produces a 4 base pair overhang, up to 240 unique, non-palindromic sequences can be used for assembly. Plasmid design and assembly In Golden Gate cloning, each DNA fragment to be assembled is placed in a plasmid, flanked by inward facing BsaI restriction sites containing the programmed overhang sequences. For each DNA fragment, the 3' overhang sequence is complementary to the 5' overhang of the next downstream DNA fragment. For the first fragment, the 5' overhang is complementary to the 5' overhang of the destination plasmid, while the 3' overhang of the final fragment is complementary to the 3' overhang of the destination plasmid. Such a design allows for all DNA fragments to be assembled in a one-pot reaction (where all reactants are mixed together), with all fragments arranged in the correct sequence. Successfully assembled constructs are selected by detecting the loss of function of a screening cassette that was originally in the destination plasmid. MoClo and Golden Braid The original Golden Gate Assembly only allows for a single construct to be made in the destination vector .
==== Insects and invertebrates ==== Most bats, especially in temperate areas, prey on insects. The diet of an insectivorous bat may span many species, including flies, mosquitos, beetles, moths, grasshoppers, crickets, termites, bees, wasps, mayflies and caddisflies. They will also eat other arthropods such as spiders, scorpions, centipedes, lobsters and shrimp. Large numbers of Mexican free-tailed bats (Tadarida brasiliensis) fly hundreds of metres above the ground in central Texas to feed on migrating moths. Species that hunt insects in flight, like the little brown bat (Myotis lucifugus) and the eastern red bat (Lasiurus borealis), may catch an insect in mid-air directly with the mouth or use their tail membranes or wings. The slow-moving brown long-eared bat (Plecotus auritus) plucks insects from vegetation, while many horseshoe bat species wait for them from their perches. Some bats may take the insect to their roost and eat it there. Arthropod-eating bats living at high latitudes have to consume prey with higher energetic value than tropical bats.
Concerns over average genital appearance or measurements are largely unavailable and make defining a successful outcome for such surgery difficult. A number of sex reassignment surgeries are available to transgender people. Although not all intersex conditions require surgical treatment, some choose genital surgery to correct atypical anatomical conditions.
== Medical uses == Etoperidone was used or was intended for use as an antidepressant in the treatment of depression. Etoperidone might be useful as a hallucinogen antidote or "trip killer" in blocking the effects of serotonergic psychedelics like psilocybin and lysergic acid diethylamide (LSD).
Sources: en.wikipedia.org
== History == Oveporexton was developed by Takeda. As of July 2025, it has completed phase III clinical trials for treatment of narcolepsy. Oveporexton was approved in China for narcolepsy type 1 in July 2026, its first global approval. Oveporexton was approved in the United States for narcolepsy type 1 in August 2026.
As weight loss depends partly on calorie intake, different kinds of calorie-reduced diets, such as those emphasizing particular macronutrients (low-fat, low-carbohydrate, etc.), have been shown to be equally effective as weight loss tools. Nonetheless, a diet low in saturated fat complemented with high fiber can be helpful for those who are found to be obese based on BMI. A low-carbohydrate diet can have the added benefits of blood sugar control in those with Type 2 Diabetes Mellitus. A low-carbohydrate diet can also improve weight loss, HDL, and cholesterol in certain individuals. Compared to a typical diet, low-carbohydrate, low-fat, and moderate macronutrient diets can all positively impact weight loss. However, weight regain is common, and the outcome of a diet can vary widely depending on the individual. Rather than focusing on the nuances of each diet type, molding one diet in a way that the person can continuously adhere in the long-term could be beneficial for weight loss.
== Venom == The venom of this species is not well studied, but it is believed that the venom is dangerously neurotoxic, like that of most elapids. A study listed the intraperitoneal (IP) LD50 of this species at 0.143 mg/kg. Venoms of the water cobras were assayed for lethality, proteolytic activity and protein content. Naja annulata annulata and Naja christyi venoms averaged 89% protein and lacked proteolytic activity. The murine intraperitoneal LD50 of N. a. annulata and N. christyi venoms were 0.143 and 0.120 mg/kg, respectively. Polyvalent antivenom produced by the South African Institute of Medical Research neutralized 575 and 200 LD50 of N. a. annulata and N. christyi venoms/ml antivenom, respectively. Cation exchange chromatography resolved four lethal peaks from N. a. annulata venom and six lethal peaks from N. christyi venom. The major lethal peaks (about 12% of total venom protein) were purified further with molecular sieve chromatography and were characterized as 61- (N. a. annulata toxin) and 62-residue (N. christyi toxin) polypeptides with four half-cystines. Elucidation of the complete amino-acid sequences indicated that these toxins belonged to the short-chain class of postsynaptic neurotoxins. Short-chain neurotoxins 1 from N. a. annulata and N. christyi had murine intraperitoneal LD50 values of 0.052 and 0.083 mg/kg, respectively, and showed over 80% homology with N. nigricollis alpha toxin. Reverse-phase analysis of another peak present in both venoms resolved a toxin that had an N-terminus identical to N. christyi short-chain neurotoxin 1.
A suitable site is to be sought throughout Germany and identified by 2031. In principle, crystalline (granite), salt or clay rock types can be considered for a repository. There will be no "ideal" site. The "best possible" site will be sought. Mining areas and regions where volcanoes have been active or where there is a risk of earthquakes are excluded. Internationally, experts are advocating storage in rock formations several hundred meters below the earth's surface. This involves building a repository mine and storing the waste there. It is then permanently sealed. Geological and technical barriers surrounding the waste are designed to keep it safe for thousands of years. For example, 300 meters of rock will separate the repository from the earth's surface. It will be surrounded by a 100-meter-thick layer of granite, salt or clay. The first waste is not expected to be stored until 2050. The Federal Office for the Safety of Nuclear Waste Management (BfE) took up its activities on September 1, 2004. Its remit includes tasks relating to nuclear safety, the safety of nuclear waste management, the site selection procedure including research activities in these areas and, later on, further tasks in the area of licensing and supervision of repositories. In the USA, Yucca Mountain was initially selected as the final storage site, but this project was temporarily halted in February 2009. Yucca Mountain was the starting point for an investigation into atomic semiotics.
Sources: en.wikipedia.org
=== Nuclear magnetic resonance spectroscopy === Metal carbonyls are often characterized by 13C NMR spectroscopy. To improve the sensitivity of this technique, complexes are often enriched with 13CO. Typical chemical shift range for terminally bound ligands is 150 to 220 ppm. Bridging ligands resonate between 230 and 280 ppm. The 13C signals shift toward higher fields with an increasing atomic number of the central metal. NMR spectroscopy can be used for experimental determination of the fluxionality. The activation energy of ligand exchange processes can be determined by the temperature dependence of the line broadening.
The Expanded Program on Immunization (EPI) in the Philippines began in 1976 through Presidential Decree No. 996 signed by President Ferdinand Marcos. And, in 1986, made a response to the Universal Child Immunization goal. The four major strategies include:
=== July === July 27, 2011: United Kingdom After figures showed that the 0.5% contraction in Q4 2010 was cancelled out by a 0.5% rise in Q1 2011, growth estimates from the ONS suggest that the growth in the UK is slowing down, after figures of 0.2% GDP increase was posted. Sovereign debt in the Eurozone and EU cause the stock market to crash from a FTSE-100 high of 6100 points to just above 5000.
=== Oxazolidines === Oxazolidines are a five-membered ring compounds consisting of three carbons, a nitrogen, and an oxygen. The oxygen and NH are the 1 and 3 positions, respectively. In oxazolidine derivatives, there is always a carbon between the oxygen and the nitrogen.
Lamont Bentley (October 25, 1973 – January 19, 2005) was an American actor and rapper best known for his role as Hakeem Campbell on the UPN sitcom Moesha. Bentley was also known for his role as Crazy K in the 1995 horror film Tales from the Hood and C-Money in the 2001 film The Wash featuring Dr. Dre and Snoop Dogg.
Sources: en.wikipedia.org
It is usually described as an immunomodulatory peptide rather than a classic circulating hormone. No endocrine gland is known to release it as a primary secretory product, and its measured presence in blood is not firmly established.
Prothymosin alpha is a much larger acidic protein, roughly 111 to 113 residues long, and the thymosin alpha-1 sequence matches its N-terminal region. The small peptide is therefore best understood as a fragment of that parent protein rather than a separate gene product.
Trials and clinical reports have examined chronic hepatitis B and C, use as a vaccine adjuvant, and supportive treatment in some immunodeficiency and oncology settings. Results vary by indication, and regulatory approval differs between countries.
It corresponds to a fragment of the larger protein prothymosin alpha, which is present in many tissues. The isolated 28-amino-acid peptide was originally obtained from thymus preparations, and the pharmaceutical product is synthesized rather than extracted. The term therefore describes both a natural fragment and a manufactured drug substance.